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 Brief Summary 
This study was designed to compare long-term arterial healing in sirolimus- and paclitaxel-
eluting stent (SES and PES) by using optical coherence tomography. At the follow-up, most 
SES showed a progressive increase in the average neointimal thickness, while PES showed 
variable changes. Long-term vessel healing were different for SES and PES. Progressive 
vessel healing was consistently observed in SES, whereas a heterogeneous process of delayed 
vessel healing was noted for PES. 
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 Abstract 
Background: Although drug-eluting stents have significantly reduced the mid-term incidence 
of target lesion revascularization, however, in vivo studies on long-term vessel healing of 
sirolimus-eluting and paclitaxel-eluting stents (SES and PES) are limited. So the aim of this 
study was to compare long-term arterial healing in SES and PES. 
Methods: We evaluated 27 SES (23 patients) and 21 PES (20 patients) by serial optical 
coherence tomography (OCT) at 6 months (mid-phase) and ≥3 years (late-phase) after 
stenting and evaluated the change of neointimal thickness (NIT), the percentages of 
uncovered and malapposed struts, peri-strut low intensity area (region around stent struts 
homogenously lower-intensity appearance than surrounding tissue), thrombus, and 
atherogenic neointima.  
Results: At the follow-up, most SES showed a progressive increase in the average NIT, while 
PES showed variable changes. Between mid-phase and late-phase, NIT increased 
significantly in SES (mid-phase: 94.1 ± 49.3, late-phase: 130.2 ± 78.7; P = 0.001), but 
decreased significantly in PES (mid-phase: 167.4 ± 122.9, late-phase: 136.0 ± 77.7; P = 0.04). 
The percentages of uncovered struts decreased significantly in SES, on the other hand, 
variable changes were observed in PES. Peri-strut low intensity area and thrombus formation 
decreased in SES, but largely remained unchanged in PES. The prevalence of atherogenic 
neointima was greater in the late-phase than the mid-phase in both groups, but similar for 
both the stents. 
Conclusions: Long-term vessel healing were different for SES and PES. Progressive vessel 
healing was consistently observed in SES, whereas a heterogeneous process of delayed vessel 
healing was noted for PES. 
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Introduction 
Drug-eluting stent (DES) have significantly reduced the mid-term incidence of in-stent 
restenosis and target lesion revascularization (TLR) by targeting acute-phase excessive 
proliferation of vascular smooth muscle cells occurring in response to mechanical injury.1 
However, late-phase clinical events, such as stent thrombosis and delayed restenosis, have been 
raised as possible concerns after first-generation DES implantation.2 Multiple causes have been 
implicated in such events, including delayed arterial healing and atherogenic changes within 
neointimal tissue (neoatherosclerosis), which have been reported as morphological features of 
first-generation DES and important risk factors.3 Further, a recent pathological study 
demonstrated significant differences in the vascular healing and differential mechanisms of late 
stent thrombosis between lesions treated with SES and PES.4 However, in-vivo studies 
comparing sequential long-term vessel healing after SES versus PES treatment are limited. 
Although first-generation DES are not among currently used standard options for the 
treatment of patients with coronary artery disease, they have been implanted in millions of 
patients worldwide. Hence, a detailed assessment of vessel healing may offer incremental 
information on patients at risk for future clinical events, potentially enabling more efficient 
patient follow-up. Therefore, the present optical coherence tomography (OCT) study focused 
on the process of long-term vessel healing after SES and PES implantation based on 
sequential OCT evaluation at mid-phase (6 months) and late-phase (≥3 years) follow-up 
among patients treated with first-generation DES. 
 
Methods 
We identified 225 consecutive patients treated with SES (Cypher; Cordis Corp., Miami 
Lakes, FL, USA) (SES-group) between October 2004 (when SES launched in Japan) and 
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May 2010, and 201 patients with PES (Taxus Express or Taxus Liberte; Boston Scientific 
Corp., Natick, MA, USA) (PES-group) between May 2007 (when PES launched in Japan) 
and May 2010.  
Of these, 158 patients with SES and 90 patients with PES underwent routine 6-month 
follow-up coronary angiography with OCT examination (mid-phase). Among these, patients 
who met the inclusion and exclusion criteria were prospectively enrolled in this study for 
sequential angiographic and OCT examinations (mid-term: 6 months, late-phase: ≥3 years). 
The inclusion criteria for this study were as follows: (a) patients with a de novo coronary 
lesion (>50% diameter stenosis) treated with SES or PES, who underwent routine 6-month 
follow-up coronary angiography and OCT; (b) native vessel size of 2.5–3.5 mm in diameter, 
and (c) stable angina or acute coronary syndrome. The exclusion criteria were as follows: (1) 
patients with ST-elevated acute myocardial infarction, (2) TLR during follow-up, and (3) 
patients unsuitable for coronary angiography due to renal dysfunction or congestive heart 
failure. Further, in order to match the timing of late-phase follow-up in the SES and PES 
groups, we excluded SES patients whose late-phase follow-up would be >5 years after 
stenting. Eventually, 27 SES from 23 patients and 21 PES from 20 patients were enrolled in 
the study (Figure 1). 
All patients were taking aspirin 100 mg/day. After stenting, patients were prescribed 
ticlopidine (200 mg/day) or clopidogrel (75 mg/day) for at least 1 year. This study was 
approved by the ethics committee of Kobe University and was carried out according to the 
guidelines of the Declaration of Helsinki. All enrolled study patients provided written 
informed consent to undergo follow-up OCT and for enrollment in this study. 
In the present study, time-domain OCT (ImageWire; LightLab Imaging, Westford, 
MA, USA) with coronary artery occlusion (HeliosTM; LightLab Imaging) was used for 
imaging at the mid- and late-phase. The entire stented length was then imaged using an 
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automatic pullback system moving at 1 mm/s. 
Offline OCT analysis was performed at 1-mm intervals using the dedicated software 
(LightLab Imaging Inc.). All images were analyzed by independent observers masked to the 
clinical presentation, lesion characteristics, and stent assignment. We used landmarks such as 
stent edge and side branches to match the location of the cross-sections between the mid-
phase and late-phase examinations.  
As a primary outcome of the quantitative OCT assessment, we measured neointimal 
thickness (NIT) of SES and PES at mid- and late-phase follow-up to compare differences of 
NIT changes between the two stents during the follow-up. Moreover, we analyzed other OCT 
findings such as the percentage of uncovered and malapposed struts to compare vessel 
healing between the stents. NIT was defined as the distance between the stent strut and lumen 
surface. An uncovered strut was defined as a strut with NIT = 0 μm. We assessed the ratio of 
uncovered struts to total struts per cross-section (RUST) and the frequency of cross-sections 
with RUST > 0.3, because a recent post-mortem study reported RUST to be the best 
morphometric predictor of late stent thrombosis.5 Malapposition was defined as a maximum 
distance of more than 170 μm in SES and 130 µm in PES between the center reflection of the 
strut and the adjacent vessel surface.6  
The frequencies of struts with a peri-strut low intensity area, a suggestive finding of 
fibrin deposition or impaired neointima maturation,7 and those of stents with an extra-stent 
lumen (ESL) were also calculated. Peri-strut low intensity area was defined as the region 
around stent struts with a homogeneous lower-intensity appearance than the surrounding 
tissue on OCT images without significant signal attenuation behind the area.8 ESL was 
defined as an external lumen of the stent struts.9  
Qualitative analysis was performed for every frame, and the frequencies of intra-stent 
thrombi and atherogenic neointima being present were calculated. An intra-stent thrombus 
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was defined as a mass protruding beyond the stent strut into the lumen with significant 
attenuation behind the mass.10 Atherogenic neointima was defined as neointima containing a 
diffuse border and signal-poor region with invisible struts underneath due to marked signal 
attenuation (Supplemental Figure S1). 
Long-term (i.e., beyond 3 years) clinical follow-up data were obtained by either a 
review of the hospital records or telephone contact. The major clinical events studied were all 
causes of death, myocardial infarction, TLR, and stent thrombosis adjudicated according to 
the Academic Research Consortium classification.11,12  
Statistical analysis was conducted with a commercially available Stat View 5.0 (SAS 
Institute, Cary, NC). Qualitative data are presented with frequencies, and quantitative data are 
shown as mean values ± SD. For continuous variables, comparisons between the 2 groups 
were performed using a 2-tailed, unpaired t-test or Wilcoxon’s test. Discrete variables are 
presented as percentages and comparisons were performed by chi-square analysis or Fisher’s 
exact test. A probability value (P) of less than 0.05 was considered statistically significant.  
 
Results 
The mean durations from stent implantation to the mid-phase and late-phase follow-up 
were 7.0 ± 2.3 months and 3.9 ± 0.4 years in the SES group, while those for PES were 7.3 ± 
1.5 months and 3.6 ± 0.7 years, respectively. All patients had taken aspirin throughout the 
follow-up period in both the groups. No significant differences were noted in medication or 
laboratory data at late-phase follow-up between the 2 groups (Table 1).   
A total of 830 matched cross-sections (mid-phase: 415, late-phase: 415) in SES and 628 
matched cross-sections (mid-phase: 314, late-phase: 314) in PES were analyzed by OCT. 
Although the mean lumen area and mean minimal lumen area did not change significantly 
from the mid-phase to late-phase follow-up, the average NIT increased significantly in SES 
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but decreased significantly in PES over the follow-up period (Table 2). Most SES cases 
showed a progressive increase in the average NIT, while various types of NIT changes were 
observed in PES cases (Figure 2a and 2b). Significant differences were observed in the NIT 
changes between SES and PES (SES: +36.1 µm vs. PES: -31.4 µm, P = 0.0003). Based on the 
qualitative assessment of neointima, PES cases with decreased NIT were categorized into 3 
types as follows: (1) NIT decrease with peri-strut low intensity area absorption, (2) regression 
of lower-intensity neointima as compared to standard neointimal tissue, and (3) regression of 
homogeneous neointima (Figure 4). Between the mid-phase and late-phase follow-up, SES 
showed a significant decrease in the percentage of uncovered struts, unlike PES, which 
showed no significant changes in both percentages (Table 2). Furthermore, most SES cases 
showed decrease in the percentage of uncovered struts during the follow-up period, while 
various types of changes such as NIT changes were observed in PES cases (Figure 2c and 
2d). The percentage of malapposed struts showed no significant changes in both stents during 
the follow-up. The percentage of peri-strut low intensity area and the incidences of thrombi 
and ESL formation decreased from the mid-phase to late-phase follow-up in SES, while no 
significant changes were noted in PES (Table 2). The percentage of peri-strut low intensity 
area was lower in PES cases with increased NIT than those with no increase at mid-phase 
follow-up (0.4% vs. 13.7%, P = 0.04). Furthermore, percentage changes in peri-strut low 
intensity area during the follow-up period were numerically higher in PES cases with 
increased NIT than in those with no increase (+2.6% vs. -8.1%, P = 0.052). Late-acquired 
thrombus tended to be more frequent in PES than in SES (Figure 5) and was associated with 
a decrease or no change in NIT between the mid- and late-phase follow-up. Further, 
significant differences were noted in NIT changes between cases with completely resolved 
thrombus and those with late-acquired thrombus (Figure 6). The prevalence of atherogenic 
neointima at late-phase was not statistically different between both the groups (SES: 14.8% 
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vs. PES: 25.0%, P = 0.39). Representative OCT images of serial qualitative OCT findings are 
shown in Supplemental Figure S2. 
Long-term clinical follow-up data after late-phase OCT examination (median: SES, 6.2 
years; PES, 4.2 years) were obtained for all patients. One patient with SES and 2 patients 
with PES required TLR; no other clinical events were noted during the study period. 
 
Discussion 
To the best of our knowledge, this is a first report that compared serial changes in 
arterial healing following different types of first-generation DES by OCT. 
Cases with delayed restenosis or late-phase TLR have been reported consistently.13 
Indeed, in this study, continued neointimal proliferation from the mid-phase to late-phase 
follow-up was observed in most of the SES-treated cases (74%) and in part of the PES-
treated cases (38%); Interestingly, although the average NIT remained comparable between 
the SES- and PES-treated lesions at ≥3 years after stenting, as observed previously,14 PES 
showed various patterns of delayed neointimal changes (decrease in 52.4% cases; increase, 
28.6%; and no change, 19.0%); however, SES showed a progressive increase. This 
discrepancy may be explained by differences in the stent platform, polymer, duration of drug 
delivery, and the pharmacologic agents themselves. For example, SES elutes sirolimus for 
only a short duration (30–90 days), while PES produces consistent elution of paclitaxel, 
which may inhibit arterial healing.  
Regression of intimal hyperplasia is frequent after bare-metal stent implantation; 
Nobuyoshi et al. reported a decrease in the extracellular matrix of the newly proliferating 
intima and subsequent fibrotic changes during the first 2–3 years after balloon angioplasty.15 
Peri-strut low intensity area around stent struts on OCT images has been suggested as 
indicative of the presence of fibrinogen surrounded by a proteoglycan extracellular matrix.10 
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We noted a lower prevalence and greater percentage of changes in peri-strut low intensity 
area with increased NIT than in those without. Therefore, we speculate that fibrotic 
maturation of the intimal hyperplasia (absorption of fluid elements such as extracellular 
matrix) and resolution of fibrin deposition may contribute to the observed regression of 
neointimal hyperplasia at the late-phase follow-up in PES. Alternatively, the neointimal tissue 
(areas hypointense to the surrounding normal tissue) detected in the mid-phase OCT images 
of several cases with decreased NIT may actually represent mural thrombi, which may have 
resolved during the follow-up period. (Figure 4b) 
We noted that both SES and PES sometimes showed delayed arterial healing, with 
persistence of uncovered struts, malapposed struts, ESL, and/or in-stent thrombi even ≥3 
years after stent deployment. However, overall, the percentage of uncovered struts and cross-
sections with RUST > 0.3 in SES decreased significantly during follow-up, with an increase 
in the frequency of completely covered stents. These results were consistent with a previous 
OCT study16 and may indicate that for SES, the healing process continued for up to 3 years. 
On the other hand, we noted various types changes in the percentage of uncovered struts were 
observed in PES cases. The percentage of uncovered struts decreased in most PES cases, 
while that increased or unchanged in some PES cases. Considering the changes of NIT and 
percentage of uncovered struts, most cases of both SES and PES have predictable healing 
patterns, however there may be some differences in vascular healing, with SES having a 
tendency to greater neointimal proliferation and struts coverage compared with PES.   
The frequency of in-stent thrombi decreased in SES, but remained unchanged in PES; 
late-acquired thrombi were frequent in PES and were always associated with neointimal 
regression; more than half of the PES-treated lesions showed neointimal regression. A 
previous experimental study showed that relative to SES, PES showed a delay in the 
reestablishment of a functional endothelium17; further, a higher incidence of thrombus 
10 
 
attachment has been demonstrated in PES than in SES in human OCT18 and angioscopic 
studies.19 Further large-scale and longitudinal study is warranted to clarify the mechanism.  
Evidence indicates that neoatherosclerosis is an important factor involved in late DES 
failure.20 In this study, the prevalence of atherogenic neointima at the late-phase follow-up 
was similar for SES and PES (overall incidence up to 5 years: 18.8%) and was relatively 
lower than that noted in a previous pathological study (overall incidence up to 6 years: 
31%).20 This discrepancy might be attributed to the differences in patient and lesion 
characteristics between the 2 studies.  
 
Study Limitations 
First, this is a study evaluating the first-generation DES using the time-domain OCT which is 
different from the current standard OCT system. Frequency-domain OCT had not been 
approved for clinical use in Japan at the time of the mid-phase follow-up, so we considered 
that it would be better to use the same imaging system in order to accurately evaluate serial 
changes of vessel healing between the mid- and the late-phase follow-up. Secondly, this is a 
single-center study with a relatively small sample size owing to the invasive nature of the 
evaluation, raising a possibility of selection bias. Thirdly, we enrolled only event-free 
patients who were available for mid- and long-term follow-up OCT. Finally, considering 
multiple comparisons with the select nature of the patient population, the results of the study 
should be interpreted primarily for generating hypotheses; moreover, P values should be 
interpreted cautiously  
 
Conclusion 
Most cases of both SES and PES have predictable healing patterns, however there may 
be some differences in vascular healing, with SES having a tendency to greater neointimal 
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proliferation and struts coverage compared with PES. Considering the relatively high 
incidence of atherogenic changes within the neointima despite statin therapy, long-term 
follow-up OCT may prove beneficial for identifying patients at risk for future ischemic 
events.  
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Table 1. Baseline clinical characteristics at late-phase follow-up 
 
Variable 
SES 
(23 patients)  
PES 
(20 patients)  
p 
Age (years) 67.9 ± 7.7 70.8 ± 6.1 0.21 
Male (%) 78.9 73.7 0.70 
BMI (kg/m2) 23.7 ± 3.5 25.4 ± 3.4 0.14 
Risk factors (%)    
     Diabetes mellitus 61.0 60.0 0.95 
     Hypertension 61.0 80.0 0.17 
     Dyslipidemia 87.0 80.0 0.54 
     History of smoking 47.8 65.0 0.26 
Hemodialysis 8.7 5.0 0.64 
Ejection fraction (%) 58.4 ± 10.3 63.2 ± 8.1 0.14 
Angina status (%)    
Stable/Unstable   91.3/8.7 85.0/15.0 0.52 
Chronic total occlusion 18.2 10.0 0.45 
Stent size    
Diameter (mm) 3.03 ± 0.39 2.93 ± 0.36 0.33 
Length (mm) 22.3 ± 6.3 20.0 ± 6.5 0.22 
Lesion characteristics (%)    
Vessel treated (LAD/LCX/RCA) 23/23/54 50/5/45 0.10 
ACC-AHA class (A/B1/B2/C) 23/42/12/23 21/42/16/21 0.82 
Duration of OCT follow-up     
     Duration of mid-phase follow-up (m) 7.0 ± 2.3 7.3 ± 1.5 0.61 
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Values are presented as mean ± SD or percentages.  
ACC-AHA, American College of Cardiology-American Heart Association lesion 
classification; ACE, angiotensin conversion enzyme; ARB, angiotensin II receptor blocker; 
BMI, body mass index; CABG, coronary artery bypass graft; MI, myocardial infarction; LAD, 
left anterior descending artery; LCX, left circumflex; PCI, percutaneous coronary intervention; 
RCA, right coronary artery. 
Duration of late-phase follow-up (y) 3.9 ± 0.4 3.6 ± 0.7 0.09 
Medication at late-phase follow-up (%)    
Aspirin 100 100 1.0 
Thienopyridine 47.4 68.4 0.19 
Statin 89.5 89.5 1.0 
ACE inhibitor or/and ARB 84.2 73.7 0.43 
Beta-blocker 57.9 36.8 0.19 
Mean duration of dual anti-platelet therapy (months) 26.4 ± 22.2 31.5 ± 15.4 0.43 
Laboratory data at late-phase follow-up    
hs-CRP (mg/dL) 0.10 ± 0.22 0.10 ± 0.13 0.98 
HDL-cholesterol (mg/dL) 46.6 ± 8.6 48.7 ± 14.0 0.58 
LDL-cholesterol (mg/dL) 80.4 ± 18.7 84.2 ± 22.6 0.58 
Triglyceride (mg/dL) 98.8 ± 32.5 119.6 ± 48.4 0.13 
HbA1c (%) 6.2 ± 0.7 5.9 ± 0.1 0.34 
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Table 2. Optical coherence tomography analysis 
 
 SES    PES   
 Mid-phase Late-phase  p  Mid-phase Late-phase  p  
Stent-based analysis          
Stent with 100% covered struts (n, %) 10 (37.0) 20 (74.1)  0.002  7 (35.0) 9 (45.0)  0.72 
Stent with ESL (n, %) 17 (63.0) 11 (40.7)  0.03  5 (25.0) 5 (25.0)  1.00 
Stent with in-stent thrombus (n, %) 8 (29.6) 3 (11.1)  0.06  7 (35.0) 6 (30.0)  0.72 
Stent with atherogenic neointima (n, %) 1 (3.7) 4 (14.8)  0.18  0 (0) 5 (25.0)  0.02 
Cross-section-based analysis          
Total number of cross-sections 415 415    314 314   
Mean lumen area (mm2) 6.4 ± 2.5 6.1 ± 2.5  0.16  5.6 ± 2.1 5.7 ± 2.0  0.64 
Mean minimal lumen area (mm2) 5.0 ± 2.5 4.7 ± 2.4  0.18  4.3 ± 2.0 4.5 ± 1.8  0.43 
Mean stent area (mm2) 6.9 ± 2.4 7.0 ± 2.4  0.53  6.9 ± 2.0 6.8 ± 2.0  0.23 
Mean neointimal area (mm2) 0.6 ± 0.5 0.9 ± 0.7  0.002  1.3 ± 1.1 1.1 ± 0.7  0.17 
Cross-section with RUST > 0.3 (n, %) 10 (2.2) 1 (0.4)  0.05  5 (2.9) 3 (0.8)  0.33 
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   ESL, extra-stent lumen. 
Strut-based analysis           
Total number of struts 3550 3476  0.28  2551 2566  0.89 
Mean neointimal thickness (μm) 94.1 ± 49.3 130.2 ± 78.7  0.0014  167.4 ± 122.9 136.0 ± 77.7  0.04 
Uncovered struts (n, %) 129 (4.1) 27 (0.9)  0.002  62 (3.2) 32 (1.5)  0.28 
Malapposed struts (n, %) 44 (1.4) 16 (0.4)  0.11  48 (2.3) 21 (0.8)  0.17 
Struts with peri-strut low intensity area (n, %) 583 (15.4) 268 (8.4)  0.03  227 (10.4) 103 (5.1)  0.06 
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 Figure legends 
 
Figure 1. Study flows 
AMI, acute myocardial infarction; CAG, coronary angiography; OCT, optical coherence 
tomography; PCI, percutaneous coronary intervention; PES, paclitaxel-eluting stent; SES, 
sirolimus-eluting stent; TLR, target lesion revascularization. 
 
 Figure 2. Different patterns of changes in average NIT and the percentage of uncovered 
struts of SES and PES  
(a) Most SES cases showed a progressive increase in the average NIT, while various NIT 
changes are observed in PES cases. (b) The percentage of NIT change patterns in SES and 
PES. NIT not changed cases was defined as NIT changes within ± 0.5 μm during the follow-
up period. (c) Most SES cases showed a decrease in the percentage of uncovered struts, while 
various changes were observed in PES cases. (d) The percentage of uncovered struts change 
patterns in SES and PES. 
NIT, neointimal thickness; SES, sirolimus-eluting stent; PES, paclitaxel-eluting stent. 
 
Figure 3. Representative cases of NIT increasing case in SES  
NIT increased with SES during the follow-up period.  
NIT, neointimal thickness; SES, sirolimus-eluting stent. 
 
Figure 4. Representative cases of temporal NIT change in PES  
(a) NIT decreased with PES during the follow-up period with peri-strut low intensity area 
absorption. (b) NIT decreased with PES showing a regression of neointima adjacent to 
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abnormal structures. (c) NIT decreased with PES showing a regression of homogeneous 
neointima. (d) NIT increased with PES. 
NIT, neointimal thickness; PES, paclitaxel-eluting stent. 
  
Figure 5. Incidence of intra-stent thrombi 
Eight thrombi in SES (30%) and 7 thrombi in PES (33%) were observed in mid-phase; 6 of 8 
thrombi in SES and 4 of 7 in PES resolved completely, while others persisted. At late-phase 
follow-up, 1 thrombus in SES and 3 in PES were newly observed. 
PES, paclitaxel-eluting stent; SES, sirolimus-eluting stent. 
 
Figure 6. Relationship between NIT changes and time course of intra-stent thrombi 
NIT changes differed significantly between cases with completely resolved thrombus and 
those with late-acquired thrombus. 
NIT, neointimal thickness. 
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